Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Cellebrite DI walked into this print with a bruised stock that was down roughly 30% over the past month and quarter. The first trading day after results told a different story. Shares climbed about 3% as investors focused less on the near term miss to internal expectations and more on what the earnings actually showed.

The headline is simple. Revenue in this quarter reached US$131.1m while Annual Recurring Revenue for Cellebrite’s digital intelligence platform stood at US$508m. At the same time management lifted the full year adjusted EBITDA margin guide into the high 20s, putting profitability discipline at center stage.

Love the profit focus at Cellebrite DI but concerned about finding other software stocks with strong recurring revenues and disciplined margins? Take a look at our hand picked list of list of solid balance sheet and fundamentals stocks (50 results).

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$131.1m vs. US$113.3m (up about 16%)
• Net Income (Q2 2026 vs Q2 2025): US$6.4m vs. US$19.5m (down about 67%)
• Basic EPS (Q2 2026 vs Q2 2025): US$0.0257 vs. US$0.0810 (down about 68%)
• Annual Recurring Revenue (ARR, Q2 2026 vs Q2 2025): US$508m vs. US$420m range implied (described as growing 21%)

Prefer clean visual charts instead of another wall of earnings tables and commentary? Get a full picture of Cellebrite DI with a clear view of its valuation setup in the company report for Cellebrite DI.

Cellebrite bull case hinges on ARR mix and margin reset

Bulls argue Cellebrite is becoming a higher quality recurring software platform with strong subscription mix, expanding ARR and improving profitability. The quarter offers partial support. ARR reached US$508m with 21% growth and subscription revenue was 91% of total, which fits the shift toward recurring software and cloud. High gross margin of 86% and a higher full year adjusted EBITDA margin guide in the high 20s back the profit discipline angle. Growth products, including Guardian and Advanced Unlocks, supplied 25% of the US$15m sequential ARR increase and Genesis already added more than US$400k ARR soon after launch. That said, the trimmed ARR outlook to US$550m to US$560m and lower uplift from Insights conversions, especially in U.S. state and local, show the recurring and AI story is not yet firing on all cylinders.

Bear case focuses on execution, guidance cuts and trust

Bears focus on execution risk, over optimistic projections and customer budget sensitivity. This quarter gives them fresh talking points. ARR and revenue missed internal expectations and full year ARR and revenue guidance were cut. Management now models large cloud and AI deals more conservatively and expects H2 net new ARR roughly in line with the prior year, which undercuts the idea of accelerating platform growth. Net income and EPS were lower than the prior year period despite strong gross margins, which keeps the earnings quality debate alive. The CEO change to Shiv Ramji and the shareholder probe following the earlier post earnings share price fall both feed concerns about forecasting credibility. At the same time, raised EBITDA margin guidance, strong free cash flow margins around 30% and solid U.S. Federal and Defense & Intelligence ARR growth show the business is not cracking, just falling short of the more aggressive growth script.

After revenue guidance cuts, insider selling and a volatile share price, review our independent risk analysis for Cellebrite DI which shows 2 important warning signs to identify any deeper structural concerns.

Take Charge Of Your Next Move

If the mix of strong ARR, guidance resets and management changes around Cellebrite DI has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a better entry setup. Once you are invested, use the Portfolio Command Center to cut through market noise and stay on top of only the most important developments that matter to your holdings. For a longer term view, tap into the crowd insight inside the Community and see how other investors are interpreting the same data. This way you can surface hidden catalysts or risks earlier and stay ahead of the market.

Seeking Alternatives Beyond Cellebrite DI?

Fresh stock ideas can move quickly, and early momentum often gets caught before the crowd catches on. Scan these curated lists while it matters and get in early.

• Chase steady compounding potential in companies with strong balance sheets and resilient earnings using our curated 83 resilient stocks with low risk scores before others notice the quieter momentum building.
• Spot early breakout potential in future infrastructure leaders by screening the curated 38 power grid technology and infrastructure stocks while many investors are still overlooking this critical backbone of modern economies.
• Ride the next wave of automation before it goes mainstream by scanning the hand picked 37 robotics and automation stocks while valuations and expectations are still under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com